2017 Annual Meeting of the American Association for the Study of Liver Diseases*

October 20-24, 2017; Washington, DC
Review Capsule Summaries, download slides, and read ClinicalThought commentaries on key studies from Washington, DC 2017.

Hepatitis C


SVR on DAA-only regimens provided a 71% reduction in de novo HCC risk.

Released: October 27, 2017

At 3 years of follow-up, 37% of participants self-reported injection drug use, with an overall reinfection rate of 2.3 per 100 person-years.

Released: October 27, 2017

Treatment generally well tolerated with no loss of HIV-1 RNA suppression.

Released: October 25, 2017

HCC incidence similar with DAAs vs IFN in cirrhotic patients and regardless of whether patients achieved SVR.

Released: October 27, 2017

No benefit noted with extension of treatment from 8 weeks to 12 weeks among noncirrhotic patients.

Released: October 27, 2017

Clinical cohort study observed no additional benefit with use of ribavirin in cirrhotic patients, nor any negative impact of baseline RASs.

Released: October 26, 2017

In this single-center study from Johns Hopkins, one third of HCV/HIV-coinfected patients did not start HCV treatment despite adherence, nursing and pharmacy support models.

Released: October 26, 2017

Large observational cohort provides clear evidence of clinical benefits of curative DAA therapy.

Released: October 27, 2017

1-year mortality risk in patients with decompensated cirrhosis 61% lower with DAA therapy vs pre-DAA era treatment.

Released: October 27, 2017

Reduction in mortality appeared greater for liver-related vs nonliver-related events.

Released: October 27, 2017

SVR12 rate of 98% with no grade 3/4 adverse events at interim analysis.

Released: October 27, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Educational grant provided by:
Gilead Sciences
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?